Adage Capital Partners GP L.L.C. Makes New $750,000 Investment in Zura Bio Limited (NASDAQ:ZURA)

Adage Capital Partners GP L.L.C. acquired a new stake in shares of Zura Bio Limited (NASDAQ:ZURA - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 300,000 shares of the company's stock, valued at approximately $750,000. Adage Capital Partners GP L.L.C. owned about 0.46% of Zura Bio at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of ZURA. American Century Companies Inc. bought a new stake in Zura Bio in the 4th quarter worth approximately $27,000. Prudential Financial Inc. purchased a new stake in shares of Zura Bio during the 4th quarter valued at about $28,000. XTX Topco Ltd bought a new stake in shares of Zura Bio during the 4th quarter valued at $44,000. SG Americas Securities LLC raised its holdings in Zura Bio by 51.6% in the 4th quarter. SG Americas Securities LLC now owns 23,005 shares of the company's stock worth $58,000 after purchasing an additional 7,828 shares during the period. Finally, Wells Fargo & Company MN lifted its position in Zura Bio by 68.6% during the fourth quarter. Wells Fargo & Company MN now owns 23,053 shares of the company's stock valued at $58,000 after purchasing an additional 9,379 shares in the last quarter. Institutional investors own 61.14% of the company's stock.

Zura Bio Stock Performance

ZURA stock traded down $0.02 on Monday, hitting $1.46. 52,565 shares of the company's stock were exchanged, compared to its average volume of 387,035. The firm has a 50 day moving average price of $1.28 and a two-hundred day moving average price of $2.20. Zura Bio Limited has a 12-month low of $0.97 and a 12-month high of $6.35. The stock has a market cap of $99.49 million, a P/E ratio of -2.75 and a beta of 0.05.

Zura Bio (NASDAQ:ZURA - Get Free Report) last released its earnings results on Tuesday, March 25th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.09. The company had revenue of $0.00 million during the quarter. Sell-side analysts expect that Zura Bio Limited will post -0.65 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Guggenheim reissued a "buy" rating and issued a $15.00 price objective on shares of Zura Bio in a research note on Wednesday, March 26th. Oppenheimer reaffirmed an "outperform" rating and set a $19.00 price objective (down from $20.00) on shares of Zura Bio in a report on Wednesday, March 26th. Chardan Capital cut their target price on shares of Zura Bio from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday, March 26th. Finally, HC Wainwright reiterated a "buy" rating on shares of Zura Bio in a research note on Thursday, April 3rd. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Zura Bio presently has a consensus rating of "Buy" and a consensus price target of $14.67.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.